Cannabinoids In Multiple Sclerosis (CAMS) Study: Safety And Efficacy Data For 12 Months Follow Up
| Effect | None |
| Trial Design | Cohort |
| Trial Length | 6+ Months |
| Number of Subjects | 502 |
| Gender | Both Genders |
| Age Range | 45-64, 65+ |
| Body Types | Average |
Following the completion of the CAMS trial and following up patients who chose to maintain THC / cannabis / placebo treatment for up to a year, it was noted that the benefits towards self-reported muscular health persisted while benefits appeared (to a clinically mild degree) on Ashworth rating scales. Fatigue and Energy, but not irritability or depression, also appeared to be benefited after 27 and 52 weeks.
| Effect | None |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 630 |
| Gender | Both Genders |
| Age Range | 45-64, 65+ |
| Body Types | Average |
In persons with multiple sclerosis given either pure THC or cannabis extracts over 15 weeks, supplementation failed to result in any improvements in physician-assessed physical mobility although patient-reported stiffness, pain, spasticity, and spasms (but not shake/tremor) appeared to be improved with supplementation. This led to improvements in sleep quality, although symptoms of fatigue and depression were unaffected.
